EBMT 2018 | CAR T-cell therapy for refractory multiple myeloma
CAR T-cell therapy has proven to be a highly effective, breakthrough therapy for treating acute lymphoblastic leukemia and acute myeloid leukemia. Here, Nikhil Munshi, MD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the results of the first-in-human CRB-401 study (NCT02658929) investigating the use of bb2121 anti-BCMA CAR T-cells in refractory multiple myeloma (MM). Speaking at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Dr Munshi remarks that while CAR T-cell therapy may be expensive, the cost of current treatments for refractory MM is not insignificant. However, given that the efficacy has shown to be exceptional, and side effects such as cytokine release syndrome occur to a lesser degree when treating MM compared with leukemia or lymphoma, CAR-T cell therapy looks to be a promising alternative option for refractory MM.
Get great new content delivered to your inboxSign up